The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) given to adolescents with obesity was associated with a one-third ...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session.

Novo Nordisk NVO has outperformed the market over the past 10 years by 6.26% on an annualized basis producing an average ...

Recent data reveals that the eurozone economy has narrowly skirted a recession, showing lukewarm yet positive growth. With ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

As Wes Streeting suggests new weight-loss jabs could be given to unemployed people to help them get back into work, doctors ...

Wegovy, produced by Danish drugmaker Novo Nordisk, made a debut here on Tuesday, 16 months after the drug obtained regulatory ...

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global ...

Weight loss drugs such as Wegovy have risen in popularity in recent months - but how exactly does it work and what are the side effects?

Wockhardt seeks approval for fast-acting insulin Aspart injection, showcasing end-to-end capabilities in biosimilar development for diabetes care.